DOCSLIB.ORG

Preclinical Activity of JNJ-7957, a Novel BCMAÂCD3 Bispecific

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Preclinical Activity of JNJ-7957, a Novel BCMAÂCD3 Bispecific Published OnlineFirst January 22, 2020; DOI: 10.1158/1078-0432.CCR-19-2299 CLINICAL CANCER RESEARCH | TRANSLATIONAL CANCER MECHANISMS AND THERAPY Preclinical Activity of JNJ-7957, a Novel BCMAÂCD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab Kristine A. Frerichs1, Marloes E.C. Broekmans1, Jhon A. Marin Soto1, Berris van Kessel1, Martijn W. Heymans2, Lisa C. Holthof1, Christie P.M. Verkleij1, Rengasamy Boominathan3, Bhavesh Vaidya3, Jocelyn Sendecki3, Amy Axel3, Francois Gaudet3, Kodandaram Pillarisetti3, Sonja Zweegman1, Homer C. Adams III3, Tuna Mutis1, and Niels W.C.J. van de Donk1 ABSTRACT ◥ Purpose: Multiple myeloma (MM) patients with disease refrac- expression did not affect activity of JNJ-7957. High T-cell tory to all available drugs have a poor outcome, indicating the need frequencies and high effector:target ratios were associated with for new agents with novel mechanisms of action. improved JNJ-7957–mediated lysis of MM cells. The PD-1/ Experimental design: We evaluated the anti-MM activity of the PD-L1 axis had a modest negative impact on JNJ-7957 activity fully human BCMAÂCD3 bispecific antibody JNJ-7957 in cell lines against tumor cells from daratumumab-na€ve MM patients. and bone marrow (BM) samples. The impact of several tumor- and Soluble BCMA impaired the ability of JNJ-7957 to kill MM host-related factors on sensitivity to JNJ-7957 therapy was also cells, although higher concentrations were able to overcome evaluated. this negative effect. Results: We show that JNJ-7957 has potent activity against Conclusions: JNJ-7957 effectively kills MM cells ex vivo, 4 MM cell lines, against tumor cells in 48 of 49 BM samples including those from heavily pretreated MM patients, whereby obtained from MM patients, and in 5 of 6 BM samples several components of the immunosuppressive BM microenvi- obtained from primary plasma cell leukemia patients. JNJ- ronment had only modest effects on its killing capacity. Our 7957 activity was significantly enhanced in patients with prior findings support the ongoing trial with JNJ-7957 as single agent daratumumab treatment, which was partially due to enhanced and provide the preclinical rationale for evaluating JNJ-7957 in killing capacity of daratumumab-exposed effector cells. BCMA combination with daratumumab in MM. Introduction small subset of normal mature B cells, as well as normal plasma cells and MM cells. BCMA is involved in differentiation of normal B In the last decade, survival of multiple myeloma (MM) patients has cells to plasma cells (3, 4). In addition, binding of a proliferation- markedly improved due to the introduction of immunomodulatory inducing ligand (APRIL) or B-cell activating factor (BAFF), which drugs (IMiD), proteasome inhibitors (PI), and the CD38-targeting has 1,000-fold lower affinity than APRIL, to BCMA promotes MM antibody daratumumab. However, patients with disease refractory to growth and induces immunosuppression in the bone marrow (BM) these agents have a very poor outcome (1). Also, newly diagnosed MM microenvironment (5–7). The selective expression of BCMA on patients with high-risk cytogenetic abnormalities have a reduced normal and malignant plasmablasts and plasma cells renders it an survival, when compared with patients with standard-risk disease (2). attractive target for novel MM treatment strategies (8, 9). Indeed, This indicates that there is still a need for new agents with novel BCMA antibody–drug conjugates and BCMA chimeric antigen recep- mechanisms of action. tor (CAR) T cells show much promise in patients with advanced B-cell maturation antigen (BCMA) is a cell membrane–bound MM (10–14). Furthermore, preclinical studies have demonstrated that tumor necrosis factor receptor family member and expressed on a BCMAÂCD3 bispecific antibodies and bispecific T-cell engagers (BiTE) have marked anti-MM activity (9, 15, 16). In addition, pre- liminary results from a phase I study show encouraging single-agent 1Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, fi 2 activity of AMG420, a BCMA-targeting BiTE (17). These bispeci c Cancer Center Amsterdam, Amsterdam, the Netherlands. Amsterdam UMC, antibodies and BiTEs redirect T cells to the BCMA-positive tumor cell, Vrije Universiteit Amsterdam, Department of Epidemiology and Biostatistics, Amsterdam, the Netherlands. 3Janssen Research and Development, LLC, Spring which is followed by perforin and granzyme release, and ultimately House, Pennsylvania. MM cell death. Killing of tumor cells by redirected T cells is inde- pendent of T-cell receptor specificity. However, MM patients with Note: Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/). advanced disease have a more immunosuppressive BM microenvi- ronment, including increased regulatory T-cell (Treg) counts, as well Prior presentation: Presented at the 23rd annual meeting of the European Hematology Association, Stockholm, 17 June 2018 (oral presentation). as upregulation of inhibitory immune checkpoints such as pro- grammed death ligand-1 (PD-L1) on MM cells and programmed cell Corresponding Author: Niels W.C.J. van de Donk, Vrije Universiteit Medical death-1 (PD-1) on T cells, which may limit the activity of bispecific Center, de Boelelaan 1117, Amsterdam 1081 HV, the Netherlands. Phone: 31-20- 4442604; Fax: 31-20-44442601; E-mail: [email protected] antibodies in these patients (18, 19). In addition, prior immunosup- pressive anti-MM therapies may hamper T-cell function and affect the Clin Cancer Res 2020;XX:XX–XX activity of these T-cell–redirecting therapies (20). doi: 10.1158/1078-0432.CCR-19-2299 Interestingly, next to its classic Fc-dependent immune effector Ó2020 American Association for Cancer Research. functions, daratumumab also has immunomodulatory effects through AACRJournals.org | OF1 Downloaded from clincancerres.aacrjournals.org on September 25, 2021. © 2020 American Association for Cancer Research. Published OnlineFirst January 22, 2020; DOI: 10.1158/1078-0432.CCR-19-2299 Frerichs et al. therapy was given according to the approved dose and schedule Translational Relevance (16 mg/kg weekly for 8 weeks, then every 2 weeks for 16 weeks, and There is a need for new agents with novel mechanisms of action every 4 weeks until progression). in multiple myeloma (MM). B-cell maturation antigen (BCMA) The study site ethics committee approved the protocols, which has been identified as a novel target for MM treatment, due to its were conducted according to the principles of the Declaration of restricted expression on plasma cells. We show that the novel Helsinki, the International Conference on Harmonization, and the BCMAÂCD3 bispecific antibody, JNJ-7957, induces potent T-cell– Guidelines for Good Clinical Practice. All patients gave written mediated killing of MM cell lines. JNJ-7957 also effectively elim- informed consent. inated primary MM cells in 48 of 49 bone marrow (BM) samples obtained from both newly diagnosed and heavily pretreated Antibodies and reagents MM patients. Interestingly, JNJ-7957 activity was significantly JNJ-7957 (JNJ-64007957) and daratumumab were provided by enhanced in patients with prior daratumumab treatment, which Janssen Pharmaceuticals. CNTO7008 (CD3 Â null), BC3B4 (BCMA Â was partially due to enhanced killing capacity of daratumumab- null), and CNTO3930 (IgG isotype control) were used as control exposed effector cells. The immunosuppressive BM microenviron- antibodies and provided by Janssen Pharmaceuticals. Recombinant ment had only limited inhibitory effects on JNJ-7957 activity. human BCMA and recombinant human APRIL were obtained Altogether, these data strengthen the preclinical rationale for the from Sigma-Aldrich. Blinatumomab (Amgen) was obtained via the ongoing clinical trial evaluating JNJ-7957. In addition, our data clinical pharmacy of Amsterdam University Medical Center. indicate that clinical evaluation of the combination of daratumu- mab and JNJ-7957 is warranted. Flow-cytometric analysis of BM and blood samples from MM patients BM-localized MM cells were identified and analyzed for cell- surface marker expression levels by staining 1.0 Â 106 cells/mL with elimination of immune suppressor cells, induction of T-cell expansion, CD138 PE, CD56 PC7, CD45 Krome Orange (all Beckman Coulter), and enhancement of the cytolytic capacity of T cells (21–26), which CD269 (BCMA) APC (BioLegend), CD274 (PD-L1) BV421, and may potentially improve the efficacy of T-cell–redirecting agents to kill CD19 APC-H7 (both Becton Dickinson). To assess CD38 expres- MM cells. sion irrespective of ongoing or recent daratumumab treatment, We therefore evaluated in this study the preclinical activity of the cells were also stained with HuMax-003 FITC, which binds to a novel fully human BCMAÂCD3 bispecific antibody (JNJ-7957), CD38 epitope distinct from the epitope bound by daratumumab which was developed using the Genmab DuoBody technology (Genmab/Janssen Pharmaceuticals). and has silenced Fc function to eliminate Fc-dependent immune Immune cell subsets in whole PB or BM aspirates were identified effector functions (27). The antitumor efficacy was tested in MM and analyzed for cell-surface marker expression levels by staining cell lines and in BM samples obtained from patients with newly 1.0 Â 106 cells/mLwithCD45KromeOrange,CD56PC7(both diagnosed (ND) or relapsed/refractory (RR) MM, including heavily Beckman Coulter), CD14 APC-H7, CD19 APC-H7, CD3 V450, pretreated patients with disease refractory to IMiDs, PIs, and CD38 CD4 APC-H7 or PE, CD8 FITC, CD45-RA APC, CD127 PE.Cy7, antibodies. We analyzed the impact of several host and tumor CD62L PE, CD274 (PD-1) BV421, CD16 APC, HLA-DR APC-H7 characteristics on ex vivo JNJ-7957 response. Furthermore, we (all Becton Dickinson), CD25 PE (Dako), and CD38 HuMax-003 þ þ evaluated the potential ability of daratumumab to improve the FITC. Na€ve T cells were defined as CD45RA CD62L , effector À À efficacy of JNJ-7957 to kill MM cells by virtue of its immunomod- memory (EM) T cells as CD45RA CD62L , central memory (CM) À þ ulatory effects. T cells as CD45RA CD62L , and terminally differentiated EM T þ À cells expressing CD45RA (TEMRA) as CD45RA CD62L (28).
Load more

Recommended publications
  • TRAIL and Cardiovascular Disease—A Risk Factor Or Risk Marker: a Systematic Review
    Journal of Clinical Medicine Review TRAIL and Cardiovascular Disease—A Risk Factor or Risk Marker: A Systematic Review Katarzyna Kakareko 1,* , Alicja Rydzewska-Rosołowska 1 , Edyta Zbroch 2 and Tomasz Hryszko 1 1 2nd Department of Nephrology and Hypertension with Dialysis Unit, Medical University of Białystok, 15-276 Białystok, Poland; [email protected] (A.R.-R.); [email protected] (T.H.) 2 Department of Internal Medicine and Hypertension, Medical University of Białystok, 15-276 Białystok, Poland; [email protected] * Correspondence: [email protected] Abstract: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a pro-apoptotic protein showing broad biological functions. Data from animal studies indicate that TRAIL may possibly contribute to the pathophysiology of cardiomyopathy, atherosclerosis, ischemic stroke and abdomi- nal aortic aneurysm. It has been also suggested that TRAIL might be useful in cardiovascular risk stratification. This systematic review aimed to evaluate whether TRAIL is a risk factor or risk marker in cardiovascular diseases (CVDs) focusing on major adverse cardiovascular events. Two databases (PubMed and Cochrane Library) were searched until December 2020 without a year limit in accor- dance to the PRISMA guidelines. A total of 63 eligible original studies were identified and included in our systematic review. Studies suggest an important role of TRAIL in disorders such as heart failure, myocardial infarction, atrial fibrillation, ischemic stroke, peripheral artery disease, and pul- monary and gestational hypertension. Most evidence associates reduced TRAIL levels and increased TRAIL-R2 concentration with all-cause mortality in patients with CVDs. It is, however, unclear Citation: Kakareko, K.; whether low TRAIL levels should be considered as a risk factor rather than a risk marker of CVDs.
    [Show full text]
  • Single-Cell RNA Sequencing Demonstrates the Molecular and Cellular Reprogramming of Metastatic Lung Adenocarcinoma
    ARTICLE https://doi.org/10.1038/s41467-020-16164-1 OPEN Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma Nayoung Kim 1,2,3,13, Hong Kwan Kim4,13, Kyungjong Lee 5,13, Yourae Hong 1,6, Jong Ho Cho4, Jung Won Choi7, Jung-Il Lee7, Yeon-Lim Suh8,BoMiKu9, Hye Hyeon Eum 1,2,3, Soyean Choi 1, Yoon-La Choi6,10,11, Je-Gun Joung1, Woong-Yang Park 1,2,6, Hyun Ae Jung12, Jong-Mu Sun12, Se-Hoon Lee12, ✉ ✉ Jin Seok Ahn12, Keunchil Park12, Myung-Ju Ahn 12 & Hae-Ock Lee 1,2,3,6 1234567890():,; Advanced metastatic cancer poses utmost clinical challenges and may present molecular and cellular features distinct from an early-stage cancer. Herein, we present single-cell tran- scriptome profiling of metastatic lung adenocarcinoma, the most prevalent histological lung cancer type diagnosed at stage IV in over 40% of all cases. From 208,506 cells populating the normal tissues or early to metastatic stage cancer in 44 patients, we identify a cancer cell subtype deviating from the normal differentiation trajectory and dominating the metastatic stage. In all stages, the stromal and immune cell dynamics reveal ontological and functional changes that create a pro-tumoral and immunosuppressive microenvironment. Normal resident myeloid cell populations are gradually replaced with monocyte-derived macrophages and dendritic cells, along with T-cell exhaustion. This extensive single-cell analysis enhances our understanding of molecular and cellular dynamics in metastatic lung cancer and reveals potential diagnostic and therapeutic targets in cancer-microenvironment interactions. 1 Samsung Genome Institute, Samsung Medical Center, Seoul 06351, Korea.
    [Show full text]
  • Role of ADAM10 and ADAM17 in Regulating CD137 Function
    International Journal of Molecular Sciences Article Role of ADAM10 and ADAM17 in Regulating CD137 Function Jana Seidel 1, Sinje Leitzke 1, Björn Ahrens 1, Maria Sperrhacke 1, Sucharit Bhakdi 2 and Karina Reiss 1,* 1 Department of Dermatology, University of Kiel, 24105 Kiel, Germany; [email protected] (J.S.); [email protected] (S.L.); [email protected] (B.A.); [email protected] (M.S.) 2 Independent Researcher, 24105 Kiel, Germany; [email protected] * Correspondence: [email protected] Abstract: Human CD137 (4-1BB), a member of the TNF receptor family, and its ligand CD137L (4-1BBL), are expressed on immune cells and tumor cells. CD137/CD137L interaction mediates bidirectional cellular responses of potential relevance in inflammatory diseases, autoimmunity and oncology. A soluble form of CD137 exists, elevated levels of which have been reported in patients with rheumatoid arthritis and various malignancies. Soluble CD137 (sCD137) is considered to represent a splice variant of CD137. In this report, however, evidence is presented that A Disintegrin and Metalloproteinase (ADAM)10 and potentially also ADAM17 are centrally involved in its generation. Release of sCD137 by transfected cell lines and primary T cells was uniformly inhibitable by ADAM10 inhibition. The shedding function of ADAM10 can be blocked through inhibition of its interaction with surface exposed phosphatidylserine (PS), and this effectively inhibited sCD137 generation. The phospholipid scramblase Anoctamin-6 (ANO6) traffics PS to the outer membrane and thus modifies ADAM10 function. Overexpression of ANO6 increased stimulated shedding, and hyperactive ANO6 led to maximal constitutive shedding of CD137.
    [Show full text]
  • CLINICAL RESEARCH PROJECT Protocol #11-H-0134 Drug Name: Eltrombopag (Promacta®) IND Number: 104,877 IND Holder: NHLBI OCD Date: January 2, 2019
    CLINICAL RESEARCH PROJECT Protocol #11-H-0134 Drug Name: eltrombopag (Promacta®) IND number: 104,877 IND holder: NHLBI OCD Date: January 2, 2019 Title: A Pilot Study of a Thrombopoietin-receptor Agonist (TPO-R agonist), Eltrombopag, in Moderate Aplastic Anemia Patients Other Identifying Words: Hematopoiesis, autoimmunity, thrombocytopenia, neutropenia, anemia, stem cells, cytokine, Promacta® (eltrombopag) Protocol Principal Investigator: *Cynthia E. Dunbar, M.D., TSCBB, NHLBI (E) Medically and Scientifically Responsible Investigator: *Cynthia E. Dunbar, M.D., TSCBB, NHLBI (E) Associate Investigators: *Georg Aue, M.D., OCD, NHLBI (E) *Neal S. Young, M.D., Chief, HB, NHLBI (E) *André Larochelle, M.D., Ph.D., CMTB, NHLBI (E) David Young, M.D., TSCBB, NHLBI (E) Susan Soto, M.S.N., R.N., Research Nurse, OCD, NHLBI(E) Olga Rios, RN, Research Nurse, OCD, NHLBI (E) Evette Barranta, R.N, Research Nurse, OCD, NHLBI (E) Jennifer Jo Kyte, DNP, Research Nurse, OCD, NHLBI (E) Colin Wu, PhD, Biostatistician, OBR, NHLBI (E) Xin Tian, PhD, Biostatistician, OBR/NHLBI (E) *Janet Valdez, MS, PAC, OCD, NHLBI (E) *Jennifer Lotter, MSHS, PA-C., OCD, NHLBI (E) Qian Sun, Ph.D., DLM, CC (F) Xing Fan, M.D., HB, NHLBI (F) Non-NIH, Non-Enrolling Engaged Investigators: Thomas Winkler, M.D., NHLBI, HB (V)# # Covered under the NIH FWA Independent Medical Monitor: John Tisdale, MD, NHLBI, OSD 402-6497 Bldg. 10, 9N116 * asterisk denotes who can obtain informed consent on this protocol Subjects of Study: Number Sex Age-range 38 Either ≥ 2 years and weight >12 kg Project Involves Ionizing Radiation? No (only when medically indicated) Off-Site Project? No Multi center trial? No DSMB Involvement? Yes 11-H-0134 1 Cynthia E.
    [Show full text]
  • A Novel BCMA/CD3 Bispecific T-Cell Engager for the Treatment
    OPEN Leukemia (2017) 31, 1743–1751 www.nature.com/leu ORIGINAL ARTICLE A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo S Hipp1, Y-T Tai2,3, D Blanset4, P Deegen5, J Wahl5, O Thomas5, B Rattel5, PJ Adam1, KC Anderson2,3 and M Friedrich5 B-cell maturation antigen (BCMA) is a highly plasma cell-selective protein that is expressed on malignant plasma cells of multiple myeloma (MM) patients and therefore is an ideal target for T-cell redirecting therapies. We developed a bispecific T-cell engager (BiTE) targeting BCMA and CD3ε (BI 836909) and studied its therapeutic impacts on MM. BI 836909 induced selective lysis of BCMA- positive MM cells, activation of T cells, release of cytokines and T-cell proliferation; whereas BCMA-negative cells were not affected. Activity of BI 836909 was not influenced by the presence of bone marrow stromal cells, soluble BCMA or a proliferation-inducing ligand (APRIL). In ex vivo assays, BI 836909 induced potent autologous MM cell lysis in both, newly diagnosed and relapsed/ refractory patient samples. In mouse xenograft studies, BI 836909 induced tumor cell depletion in a subcutaneous NCI-H929 xenograft model and prolonged survival in an orthotopic L-363 xenograft model. In a cynomolgus monkey study, administration of BI 836909 led to depletion of BCMA-positive plasma cells in the bone marrow. Taken together, these results show that BI 836909 is a highly potent and efficacious approach to selectively deplete BCMA-positive MM cells and represents a novel immunotherapeutic for the treatment of MM.
    [Show full text]
  • RANK Receptor Oligomerisation in the Regulation of Nfkb Signalling
    S DAS and others RANK oligomerisation and 53:1 81–91 Research signalling Open Access RANK receptor oligomerisation in the regulation of NFkB signalling Correspondence S Das, I Sepahi, A Duthie, S Clark and J C Crockett should be addressed to J C Crockett Bone and Musculoskeletal Research Programme, Division of Applied Medicine, Institute of Medical Sciences, Email University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK [email protected] Abstract The interaction of receptor activator of NFkB (RANK), a member of the tumour necrosis Key Words factor receptor superfamily, with RANK ligand is crucial for the formation, function and " oligomerisation survival of osteoclasts. The role of the cytoplasmic oligomerisation domain (pre-ligand " RANK assembly domain; PLAD or ‘IVVY’ motif) in the ligand-dependent activation of downstream " NFkB NFkB signalling has not been studied previously. The discovery of truncating mutations of " osteopetrosis TNFRSF11A (W434X and G280X that lack the PLAD) as the cause of rare cases of osteoclast- poor osteopetrosis offered the opportunity for functional study of this region. Recapitu- lating the W434X mutation by transcription activator-like effector nuclease (TALEN)- mediated targeted disruption of Tnfrsf11a within the region homologous to W434X in the mouse macrophage-like cell line RAW264.7 impaired formation of osteoclast-like cells. Using overexpression studies, we demonstrated that, in contrast to WT-RANK, the absence of the PLAD in G280X-RANK and W434X-RANK prevented ligand-independent but not ligand- dependent oligomerisation. Cells expressing W434X-RANK, in which only two of the three TRAF6-binding motifs are present, continued to exhibit ligand-dependent NFkB signalling.
    [Show full text]
  • T Lymphocytes in the Synovial Fluid of Patients with Active Rheumatoid
    Clinical and Experimental Rheumatology 2001; 19: 317-320. BRIEF PAPER T lymphocytes in the ABSTRACT in the pathogenesis of the disease (4). Objective. To assess the percentage of The human CD 134 (OX40) cell sur- synovial fluid of patients T ly m p h o cy t e s , b e a ring CD134, a faceantigen, a 50-kDa membrane-asso- with active rheumatoid member of the TNF receptor superfam - ciated glycoprotein, is a member of the arthritis display CD134- i ly, p ri m a ri ly found on autore a c t ive tumor necrosis factor (TNF) receptor CD4+ T cells in the peripheral blood superfamily, which is found primarily OX40 surface antigen (PB) and synovial fluid (SF) of rheu - on activated CD4+ cells and not on matoid arthritis (RA) patients. normal resting peripheral blood lym- R. Giacomelli, M e t h o d s . The surface ex p ression of phocytes (5). Its interaction with the A. Passacantando, CD134 on SF and PB mononu cl e a r specific ligand (CD134L – OX40L), a 1 cells was performed by flow cytometry type II membrane protein (6) generally R. Perricone , in 25 RA patients and correlated to the expressed on activated B lymphocytes I. Parzanese, M. Rascente, disease activity. (7), antigen presenting cells, and acti- G. Minisola2, G. Tonietti Results. CD134 expression on CD3+, vated endothelial cells (8) is, on one CD4+, CD8+ and CD25+ cells was hand, an efficient costimulatory signal Clinica Medica, University of L’Aquila; higher in SF than in PB of RA patients for CD4+ T cell-dependent humora l 1Immunologia Clinica, University of Tor ( P < 0.001).
    [Show full text]
  • Jimmunol.1601908.Full.Pdf
    Metabolic Reprogramming Commits Differentiation of Human CD27 +IgD+ B Cells to Plasmablasts or CD27−IgD− Cells This information is current as Masataka Torigoe, Shigeru Iwata, Shingo Nakayamada, Kei of October 3, 2021. Sakata, Mingzeng Zhang, Maiko Hajime, Yusuke Miyazaki, Manabu Narisawa, Koji Ishii, Hirotaka Shibata and Yoshiya Tanaka J Immunol published online 16 June 2017 http://www.jimmunol.org/content/early/2017/06/15/jimmun ol.1601908 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2017/06/15/jimmunol.160190 Material 8.DCSupplemental http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on October 3, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2017 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published June 16, 2017, doi:10.4049/jimmunol.1601908 The Journal of Immunology Metabolic Reprogramming Commits Differentiation of Human CD27+IgD+ B Cells to Plasmablasts or CD272IgD2 Cells Masataka Torigoe,*,† Shigeru Iwata,* Shingo Nakayamada,* Kei Sakata,*,‡ Mingzeng Zhang,* Maiko Hajime,* Yusuke Miyazaki,* Manabu Narisawa,* Koji Ishii,† Hirotaka Shibata,† and Yoshiya Tanaka* B cells play a crucial role in the pathogenesis of autoimmune diseases, such as systemic lupus erythematosus (SLE).
    [Show full text]
  • Lipid Rafts Are Important for the Association of RANK and TRAF6
    EXPERIMENTAL and MOLECULAR MEDICINE, Vol. 35, No. 4, 279-284, August 2003 Lipid rafts are important for the association of RANK and TRAF6 Hyunil Ha1,3, Han Bok Kwak1,2,3, Introduction Soo Woong Lee1,2,3, Hong-Hee Kim2,4, 1,2,3,5 Osteoclasts are multinucleated giant cells responsible and Zang Hee Lee for bone resorption. These cells are differentiated from 1 hematopoietic myeloid precursors of the monocyte/ National Research Laboratory for Bone Metabolism macrophage lineage (Suda et al., 1992). For the dif- 2Research Center for Proteineous Materials 3 ferentiation of osteoclast precursors into mature osteo- School of Dentistry clasts, a cell-to-cell interaction between osteoclast Chosun University, Gwangju 501-759, Korea 4 precursors and osteoblasts/stromal cells are required Department of Cell and Developmental Biology (Udagawa et al., 1990). Recently, many studies have College of Dentistry, Seoul National University provided ample evidences that the TNF family mem- Seoul 110-749, Korea κ 5 ber RANKL (receptor activator of NF- B ligand; also Corresponding author: Tel, 82-62-230-6872; known as ODF, OPGL, and TRANCE) is expressed Fax, 82-62-227-6589; E-mail, [email protected] on the surface of osteoblasts/stromal cells and es- sential for osteoclast differentiation (Anderson et al., Accepted 19 June 2003 1997; Yasuda et al., 1998; Takahashi et al., 1999). When its receptor RANK was stimulated by RANKL, Abbreviations: MAPK, mitogen-activated protein kinase; MCD, several TNF receptor-associated factors (TRAFs), methyl-β-cyclodextrin; RANK, receptor activator of NF-κB; TLR, especially TRAF6, can be directly recruited into RANK Toll-like receptor; TNFR, TNF receptor; TRAF, TNF receptor- cytoplasmic domains and may trigger downstream associated factor signaling molecules for the activation of NF-κB and mitogen activated protein kinases (MAPKs) (Darnay et al., 1998; Wong et al., 1998; Kim et al., 1999).
    [Show full text]
  • High TNFRSF12A Level Associated with MMP-9 Overexpression Is
    RESEARCH ARTICLE High TNFRSF12A level associated with MMP-9 overexpression is linked to poor prognosis in breast cancer: Gene set enrichment analysis and validation in large-scale cohorts Jungho Yang1, Kyueng-Whan Min2*, Dong-Hoon Kim1*, Byoung Kwan Son3, Kyoung Min Moon4, Young Chan Wi5, Seong Sik Bang5, Young Ha Oh2, Sung-Im Do1, Seoung Wan Chae1, Sukjoong Oh6, Young Hwan Kim7, Mi Jung Kwon8 a1111111111 1 Departments of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, a1111111111 Seoul, Republic of Korea, 2 Department of Pathology, Hanyang University Guri Hospital, Hanyang University a1111111111 College of Medicine, Guri, Gyeonggi-do, Republic of Korea, 3 Department of Internal Medicine, Eulji Hospital, a1111111111 Eulji University School of Medicine, Seoul, Republic of Korea, 4 Department of Internal Medicine, Gangneung a1111111111 Asan Hospital, University of Ulsan College of Medicine, Gangneung, Republic of Korea, 5 Department of Pathology, Hanyang University College of Medicine, Seoul, Republic of Korea, 6 Departments of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, 7 Departments of Nuclear Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, 8 Department of Pathology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Gyeonggi-do, Republic of Korea OPEN ACCESS * [email protected](KWM); [email protected](DHK) Citation: Yang J, Min K-W, Kim D-H, Son BK, Moon KM, Wi YC, et al. (2018) High TNFRSF12A level associated with MMP-9 overexpression is linked to poor prognosis in breast cancer: Gene set Abstract enrichment analysis and validation in large-scale cohorts.
    [Show full text]
  • The Role of the CD134-CD134 Ligand Costimulatory Pathway in Alloimmune Responses in Vivo
    The Role of the CD134-CD134 Ligand Costimulatory Pathway in Alloimmune Responses In Vivo This information is current as Xueli Yuan, Alan D. Salama, Victor Dong, Isabela Schmitt, of September 27, 2021. Nader Najafian, Anil Chandraker, Hisaya Akiba, Hideo Yagita and Mohamed H. Sayegh J Immunol 2003; 170:2949-2955; ; doi: 10.4049/jimmunol.170.6.2949 http://www.jimmunol.org/content/170/6/2949 Downloaded from References This article cites 51 articles, 21 of which you can access for free at: http://www.jimmunol.org/content/170/6/2949.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 27, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2003 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology The Role of the CD134-CD134 Ligand Costimulatory Pathway in Alloimmune Responses In Vivo1 Xueli Yuan,* Alan D. Salama,* Victor Dong,* Isabela Schmitt,* Nader Najafian,* Anil Chandraker,* Hisaya Akiba,† Hideo Yagita,† and Mohamed H.
    [Show full text]
  • Double-Negative (CD27-Igd-) B Cells Are Expanded in NSCLC And
    Centuori et al. J Transl Med (2018) 16:30 https://doi.org/10.1186/s12967-018-1404-z Journal of Translational Medicine RESEARCH Open Access Double‑negative ­(CD27−IgD−) B cells are expanded in NSCLC and inversely correlate with afnity‑matured B cell populations Sara M. Centuori1, Cecil J. Gomes2, Samuel S. Kim3, Charles W. Putnam1,3, Brandon T. Larsen4, Linda L. Garland1,5, David W. Mount6 and Jesse D. Martinez1,7* Abstract Background: The presence of B cells in early stage non-small cell lung cancer (NSCLC) is associated with longer survival, however, the role these cells play in the generation and maintenance of anti-tumor immunity is unclear. B cells diferentiate into a variety of subsets with difering characteristics and functions. To date, there is limited informa- tion on the specifc B cell subsets found within NSCLC. To better understand the composition of the B cell populations found in NSCLC we have begun characterizing B cells in lung tumors and have detected a population of B cells that are ­CD79A+CD27−IgD−. These ­CD27−IgD− (double-negative) B cells have previously been characterized as uncon- ventional memory B cells and have been detected in some autoimmune diseases and in the elderly population but have not been detected previously in tumor tissue. Methods: A total of 15 fresh untreated NSCLC tumors and 15 matched adjacent lung control tissues were dissociated and analyzed by intracellular fow cytometry to detect the B cell-related markers CD79A, CD27 and IgD. All ­CD79A+ B cells subsets were classifed as either naïve ­(CD27−IgD+), afnity-matured ­(CD27+IgD−), early memory/germinal center cells ­(CD27+IgD+) or double-negative B cells ­(CD27−IgD−).
    [Show full text]